Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug ALN-CIDEB targets fatty liver in early trial

NCT ID NCT06836609

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests an experimental drug called ALN-CIDEB in adults with fatty liver conditions (MASLD or MASH). The main goal is to check safety and tolerability, and also to see if the drug can reduce liver fat. About 132 participants will receive either the drug or a placebo. This is an early-stage trial, so results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ALN-CIDEB (an experimental drug)
What this could lead to
If it works, this could point toward a treatment that reduces liver fat and controls MASLD/MASH, potentially preventing progression to more severe liver damage.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 132 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

Contacts and locations

Locations

  • Adobe Clinical Research

    RECRUITING

    Tucson, Arizona, 85712, United States

  • Arizona Liver Health

    RECRUITING

    Chandler, Arizona, 85225, United States

  • Parexel International Early Phase Clinical Unit

    RECRUITING

    Harrow, London, HA1 3UJ, United Kingdom

  • Richmond Pharmacology Limited

    RECRUITING

    London, Greater London, SE1 1YR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.